Sex: M
Vaccine: COVID19, UNK
Symptoms: Psoriasis, Visual impairment
Clinical narrative: recurrent eyes inflammation; eye site getting worse; psoriasis spots on elbows; right eye pressure was 21/left eye pressure was 12; eye color goes down; possible reoccurrence of glaucoma; This is a solicited report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4366900-00.  A 78-year-old male patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) intramuscular for covid-19 immunisation; adalimumab (HUMIRA), since Dec2021 (ongoing) (Batch/Lot number: unknown) at unk (citrate free), subcutaneous for psoriatic arthropathy, rheumatoid arthritis, psoriasis. The patient's relevant medical history included: "Trouble seeing colors" (unspecified if ongoing); "Glaucoma" (unspecified if ongoing); "High eye pressure" (unspecified if ongoing); "Uveitis" (unspecified if ongoing); "Eye inflammation" (unspecified if ongoing); "Three eye surgeries" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: EYE COLOUR CHANGE (non-serious) with onset Mar2022, outcome "recovering", described as "eye color goes down"; INTRAOCULAR PRESSURE TEST ABNORMAL (non-serious) with onset 14Apr2022, outcome "not recovered", described as "right eye pressure was 21/left eye pressure was 12"; GLAUCOMA (non-serious) with onset 2022, outcome "not recovered", described as "possible reoccurrence of glaucoma"; EYE INFLAMMATION (non-serious), outcome "recovering", described as "recurrent eyes inflammation"; VISUAL IMPAIRMENT (non-serious), outcome "not recovered", described as "eye site getting worse"; PSORIASIS (non-serious), outcome "not recovered", described as "psoriasis spots on elbows". The patient underwent the following laboratory tests and procedures: Intraocular pressure test: (14Apr2022) Unknown results. The action taken for adalimumab was dosage not changed.  Causality for Humira (Adalimumab): The reporter's causality for the event(s) of eye color goes down and right eye pressure was 21/left eye pressure was 12 with Humira 40mg/0.4ml (adalimumab) was no reasonable possibility. The reporter's causality for the event(s) of possible reoccurrence of glaucoma and psoriasis spots on elbows was not provided. The reporter's causality for the event(s) of recurrent eyes inflammation and eye site getting worse with Humira 40mg/0.4ml (adalimumab) was a reasonable possibility.  The reporter considered "eye color goes down", "right eye pressure was 21/left eye pressure was 12", "possible reoccurrence of glaucoma", "recurrent eyes inflammation", "eye site getting worse" and "psoriasis spots on elbows" related to BNT162b2.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on the information in the case report, a possible causal relationship between the reported events and the suspect drug BNT162B2 cannot be completely excluded.   The impact of this report on the benefit/risk profile of the Pfizer drug is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.